Moderna said on Wednesday that its coronavirus vaccine works in children aged six months to six years old and that it plans to seek approval from global health regulators.
The pharmaceutical company said in a statement on Wednesday that on its second phase in a three-part COVID-19 vaccine study on children aged six months to six years was successful.
The study involved around 6,700 children in two groups — aged six months to under two years old and two years to under six years old, the company said.
"We believe these latest results from the KidCOVE study are good news for parents of children under 6 years of age," said Moderna CEO Stéphane Bancel in the statement. "We now have clinical data on the performance of our vaccine from infants six months of age through older adults."
The company said it would now seek approval from the US Food and Drug Administration, the European Medicines Agency, and other global regulators.
This story is developing. Please check back for updates.